天津医药 ›› 2026, Vol. 54 ›› Issue (11): 1172-1176.doi: 10.11958/20260822

• 临床研究 • 上一篇    下一篇

外周血NLR、PLR及CD4+/CD8+在结肠癌术后复发患者化疗前后的变化及与疗效的关系

徐扬1(), 王永生2, 王蕾1, 储雪雁3,△()   

  1. 1 联勤保障部队北戴河康复疗养中心综合内科 (邮编 066100)
    2 联勤保障部队北戴河康复疗养中心外科 (邮编 066100)
    3 联勤保障部队临潼康复疗养中心疗养一科
  • 收稿日期:2026-04-01 修回日期:2026-07-06 出版日期:2026-11-15 发布日期:2026-11-10
  • 通讯作者: 储雪雁 E-mail:XUYang028@163.com;2196027607@qq.com
  • 作者简介:徐扬(1968),女,主任医师,主要从事恶性实体瘤的内科治疗及早癌筛查方面研究。E-mail:XUYang028@163.com

Changes of peripheral blood NLR, PLR and CD4+/CD8+ ratio in patients with postoperative recurrence of colon cancer before and after chemotherapy and their relationship with treatment efficacy

XU Yang1(), WANG Yongsheng2, WANG Lei1, CHU Xueyan3,△()   

  1. 1 Comprehensive Internal Medicine, Joint Logistic Support Force Beidaihe Rehabilitation and Rehabilitation Center, Qinhuangdao 066100, China
    2 Department of Surgery, Joint Logistic Support Force Beidaihe Rehabilitation and Rehabilitation Center, Qinhuangdao 066100, China
    3 Department of Rehabilitation, Joint Logistic Support Force Lintong Rehabilitation and Recuperation Center
  • Received:2026-04-01 Revised:2026-07-06 Published:2026-11-15 Online:2026-11-10
  • Contact: CHU Xueyan E-mail:XUYang028@163.com;2196027607@qq.com

摘要:

目的 探讨外周血中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)及CD4+、CD8+、CD4+/CD8+在结肠癌术后复发患者化疗前后的水平变化及与疗效的关系。方法 回顾性收集147例结肠癌术后复发化疗患者的临床资料,并根据疗效分为有效组(93例)和无效组(54例)。检测患者化疗前后NLR、PLR及CD4+、CD8+、CD4+/CD8+水平,比较2组化疗前后及有效组不同TNM分期上述指标的差异。采用Spearman秩相关分析各指标与化疗疗效及TNM分期的相关性。结果 化疗后,有效组NLR、PLR水平及CD8+低于无效组,CD4+/CD8+高于无效组(P<0.05);2组CD4+差异无统计学意义(P>0.05)。有效组中,Ⅱ、Ⅲ、Ⅳ期患者的NLR、PLR、CD8+水平依次升高,CD4+、CD4+/CD8+水平依次降低(P<0.05)。Spearman秩相关分析显示,NLR、PLR、CD8+与化疗疗效呈负相关,与TNM分期呈正相关(P<0.05);CD4+、CD4+/CD8+与化疗疗效呈正相关,与TNM分期呈负相关(P<0.05)。结论 外周血炎性指标和免疫指标在结肠癌术后复发化疗患者中呈显著变化,与结肠癌临床病理特征有关,可作为预测化疗疗效的潜在指标。

关键词: 结肠肿瘤, 肿瘤复发, 肿瘤分期, 中性粒细胞/淋巴细胞比值, 血小板/淋巴细胞比值, 免疫指标, 化疗方案

Abstract:

Objective To investigate the changes in peripheral blood neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), CD4+, CD8+ and CD4+/CD8+ ratio before and after chemotherapy in patients with recurrent colon cancer following surgery, and to evaluate their relationship with treatment efficacy. Methods Clinical data of 147 patients with postoperative recurrent colon cancer who received chemotherapy were retrospectively collected. Based on treatment response, patients were divided into the effective group (n=93) and the ineffective group (n=54). Peripheral blood levels of NLR, PLR, CD4+, CD8+ and CD4+/CD8+ ratio were measured before and after chemotherapy. These parameters were compared between the two groups before and after chemotherapy, and the effective group at different TNM stages. Spearman rank correlation analysis was used to assess the relationship between these parameters with chemotherapeutic efficacy and TNM stage. Results After chemotherapy, the levels of NLR, PLR and CD8+ were significantly lower in the effective group than those in the ineffective group, while CD4+/CD8+ ratio was higher than those of the ineffective group (P < 0.05). There was no significant difference in CD4+ level between the two groups (P > 0.05). In the effective group, levels of NLR, PLR and CD8+ of patients with stage Ⅱ, Ⅲ and Ⅳ increased successively, and levels of CD4+ and CD4+/CD8+ ratio decreased successively (P<0.05). Spearman rank correlation analysis revealed that NLR, PLR and CD8+ were negatively correlated with chemotherapeutic efficacy and positively correlated with TNM stage (P < 0.05), whereas CD4+ and CD4+/CD8+ ratio were positively correlated with chemotherapeutic efficacy and negatively correlated with TNM stage (P<0.05). Conclusion Peripheral blood inflammatory and immune markers show significant changes in patients with postoperative recurrence of colon cancer receiving chemotherapy, which are associated with clinicopathological characteristics. These markers may serve as potential indicators for predicting chemotherapeutic efficacy.

Key words: colonic neoplasms, neoplasm recurrence, neoplasm staging, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, immune indicators, chemotherapy regimens

中图分类号: